FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523632-39-00

Enrollment

Registered

2026-08-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid lymphoma

Brief summary

Progression Free Survival (PFS) defined as the time from allo-HSCT to AML relapse or death

Detailed description

Conditioning related toxicity according to CTCAE, rate of graft failure, Cumulative incidence of neutrophil and platelet recovery, Cumulative incidence of acute GVHD, Cumulative incidence of chronic GVHD, Cumulative incidence of NRM, Probability of Overall Survival, Probability of GVHD, Prevalence of immunosuppressive therapy (IST) and GVHD at 3, 6, 9, 12 months

Interventions

DRUGCICLOSPORIN

DRUGMYCOPHENOLATE MOFETIL

DRUGFludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion

DRUGCYCLOPHOSPHAMIDE

DRUGTrecondi 5 g powder for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS) defined as the time from allo-HSCT to AML relapse or death	—

Secondary

Measure	Time frame
Conditioning related toxicity according to CTCAE, rate of graft failure, Cumulative incidence of neutrophil and platelet recovery, Cumulative incidence of acute GVHD, Cumulative incidence of chronic GVHD, Cumulative incidence of NRM, Probability of Overall Survival, Probability of GVHD, Prevalence of immunosuppressive therapy (IST) and GVHD at 3, 6, 9, 12 months	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 18, 2026